"An International, Double-blind, Randomised, Placebo-Controlled Phase III Study to Evaluate the Effect of Dapagliflozin on Reducing CV Death or Worsening Heart Failure in Patients with Heart Failure with Preserved Ejection Fraction (HFpEF) DELIVER - Dapagliflozin Evaluation to Improve the LIVEs of Patients with PReserved Ejection Fraction Heart Failure "
2022-06-29
عنوان الدراسة
"An International, Double-blind, Randomised, Placebo-Controlled Phase III Study to Evaluate the Effect of Dapagliflozin on Reducing CV Death or Worsening Heart Failure in Patients with Heart Failure with Preserved Ejection Fraction (HFpEF) DELIVER - Dapagliflozin Evaluation to Improve the LIVEs of Patients with PReserved Ejection Fraction Heart Failure "
داعم الدراسة
AstraZeneca
دواء الدراسة
Dapagliflozin
رقم بروتوكول الدراسة
D169CC00001
حالة الدراسة
Completed
موقع الدراسة
KKUH
مرحلة الدراسة
3
评论与建议
如对政府服务有任何咨询或意见,请填写所需信息。